GlassScriptPhysician profile
Phaelon H Silva
NPI 1225028285
$5,084.18
in general payments reported to CMS, 2019-2025
25 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $1,277 · 2021: $98.25 · 2022: $479 · 2023: $857 · 2024: $1,480 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,442 · Travel and Lodging: $1,170 · Gift: $22.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.44 |
| Travel and Lodging | $1,169.61 |
| Gift | $22.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,862.66 | 2020-2024 | Da Vinci Surgical System |
| Abbvie INC. | $756.34 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Sumitomo Pharma America, INC. | $191.56 | 2023-2025 | Myfembree, Gemtesa |
| Organon LLC | $137.93 | 2021-2025 | Jada System, Nexplanon |
| Pfizer INC. | $128.48 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.77 | 2019-2025 | |
| Coopersurgical, INC. | $125.66 | 2019-2022 | |
| Hologic Sales and Service, LLC | $105.62 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Exeltis, USA INC. | $81.24 | 2022-2023 | Slynd |
| Allergan, INC. | $75.79 | 2019 | |
| Astellas Pharma US INC | $69.68 | 2025 | Veozah |
| Lupin INC. | $64.02 | 2019 | |
| Meditrina | $55.94 | 2022 | |
| Myovant Sciences INC. | $46.60 | 2022 | |
| Therapeuticsmd, INC. | $40.27 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $37.12 | 2024 | Bulkamid |
| Solventum Corporation | $32.44 | 2025 | V.A.C. Veraflo, Prevena, Activ.A.C. |
| Boston Scientific Corporation | $28.37 | 2025 | Bulkamid |
| Ge Healthcare | $27.22 | 2019 | |
| Mayne Pharma Commercial LLC | $23.13 | 2023 | |
| Idorsia Pharmaceuticals US INC | $16.88 | 2022 | |
| Kci USA, INC. | $15.00 | 2023 | Activ.A.C., Prevena |
| Amgen INC. | $12.83 | 2019 | |
| Merck Sharp & Dohme LLC | $12.07 | 2019 | |
| Baxter Healthcare | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phaelon Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.